Affinity Proteomic Profiling of Plasma, Cerebrospinal Fluid, and Brain Tissue Within Multiple Sclerosis

J Proteome Res. 2014 Nov 7;13(11):4607-19. doi: 10.1021/pr500609e. Epub 2014 Oct 1.

Abstract

The brain is a vital organ and because it is well shielded from the outside environment, possibilities for noninvasive analysis are often limited. Instead, fluids taken from the spinal cord or circulatory system are preferred sources for the discovery of candidate markers within neurological diseases. In the context of multiple sclerosis (MS), we applied an affinity proteomic strategy and screened 22 plasma samples with 4595 antibodies (3450 genes) on bead arrays, then defined 375 antibodies (334 genes) for targeted analysis in a set of 172 samples and finally used 101 antibodies (43 genes) on 443 plasma as well as 573 cerebrospinal spinal fluid (CSF) samples. This revealed alteration of protein profiles in relation to MS subtypes for IRF8, IL7, METTL14, SLC30A7, and GAP43. Respective antibodies were subsequently used for immunofluorescence on human post-mortem brain tissue with MS pathology for expression and association analysis. There, antibodies for IRF8, IL7, and METTL14 stained neurons in proximity of lesions, which highlighted these candidate protein targets for further studies within MS and brain tissue. The affinity proteomic translation of profiles discovered by profiling human body fluids and tissue provides a powerful strategy to suggest additional candidates to studies of neurological disorders.

Keywords: CSF; antibodies; brain tissue; immunofluorescence; multiple sclerosis; plasma; suspension bead arrays.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies
  • Brain / metabolism*
  • Cerebrospinal Fluid / metabolism*
  • Fluorescent Antibody Technique
  • Humans
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / metabolism*
  • Netherlands
  • Proteome / metabolism*
  • Proteomics / methods*

Substances

  • Antibodies
  • Proteome